Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Nokia Corp (NOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Nokia Corp — how do they compare? Definium Therapeutics Inc. Common Shares trades at $34.01 (market cap $4.71B), while Nokia Corp trades at $10.34 (market cap $60.13B). The key difference: Nokia Corp is far larger — about 12.8× Definium Therapeutics Inc. Common Shares's market cap, and Nokia Corp pays a 1.54% dividend while Definium Therapeutics Inc. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Nokia Corp for 66 Days on average.
| DFTX | NOK | |
|---|---|---|
Market Cap | $4.71B | $60.13B |
Volume | 1,966,636 | 71,806,452 |
Sector | Health | Technology |
52-Week High | $48.45 | $16.83 |
52-Week Low | $10.68 | $5.18 |
Typical Hold Time | 0 Days | 66 Days |
Enterprise Value | $3.67B | $58.14B |
Dividend Yield | — | 1.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Nokia (NOK) trades at $10.14, down 7.57% over the past day, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $19.89 billion with a net income margin of 3.47%. Recent news highlights partnerships with Microsoft and ICEYE for AI and satellite communications, driving positive sentiment.
The outlook is supported by strong analyst consensus with a $17.50 price target and 61.5% buy ratings, but risks include volatile cash flows and high valuation multiples. Upside potential exists from AI infrastructure demand, while execution and competitive pressures remain key concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
